Xerostomia in survivors of severe COVID-19: findings from a Latin American cohort.
Paola Andrea Escobar Villegas, Brayan Daniel Cordoba-Melo, Juan Pablo Arango-Ibanez, Maria Camila Naranjo-Ramirez, Mario Miguel Barbosa, Andrés Felipe Casanova Rojas, Andrés Fernando Mina Sánchez, Cesar José Herrera, Miguel Ángel Quintana Da Silva, Andrés Felipe Buitrago Sandoval, María Lorena Coronel Gilio, Freddy Pow Chon Long, Liliana Cárdenas Aldaz, Juan Esteban Gomez-Mesa
Abstract
Open AccessObjectives: SARS-CoV-2 primary affects the respiratory tract; however, evidence suggests the oral cavity can be involved in severe COVID-19 survivors. This study investigates factors associated with xerostomia in severe COVID-19 survivors from a Latin American cohort. Materials and methods: A prospective multicenter study from the Latin American Registry of Cardiovascular Disease and COVID-19, analyzed data on 272 severe COVID-19 patients from 7 institutions in 5 countries (Colombia, Dominican Republic, Ecuador, Argentina, and Paraguay). Long-term follow-up assessed demographics characteristics, comorbidities, lifestyle, cardiovascular complications, and oral health. Logistic regression in R software identified factors associated with xerostomia. Results: Xerostomia was reported in 20.6% of patients. Among affected individuals, 53.6% were female, while women represented 35.6% of those without the condition. In the overall cohort, the most common comorbidities were overweight/obesity (57.0%), hypertension (55.9%), and dyslipidemia (32.0%). Patients with xerostomia had higher rates of dyslipidemia (48.2% vs. 27.8%) and asthma/COPD (16.1% vs. 4.2%) compared to the group without xerostomia. In multivariable logistic regression, asthma/COPD (aOR: 5.14; 95% CI: 1.76-15.7), palpitations (aOR: 2.47; 95% CI: 1.04-5.94), and chest pain (aOR: 3.74; 95% CI: 1.67-8.43) were independently associated with xerostomia. Conversely, male sex was associated with lower odds of reporting xerostomia (aOR: 0.47; 95% CI: 0.24-0.89). Conclusion: These findings underscore the need for clinicians to actively assess oral health symptoms such as xerostomia in post-COVID care, particularly in patients with cardiopulmonary comorbidities and persistent systemic symptoms.